Comparative Pharmacology
Head-to-head clinical analysis: GILOTRIF versus NINTEDANIB ESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILOTRIF versus NINTEDANIB ESYLATE.
GILOTRIF vs NINTEDANIB ESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GILOTRIF (afatinib) is an irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4. It binds covalently to the ATP-binding pocket of the kinase domain, blocking downstream signaling pathways involved in cell proliferation, survival, and angiogenesis.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
40 mg orally once daily for first-line treatment of EGFR mutation-positive non-small cell lung cancer; may be increased to 50 mg if tolerated.
150 mg orally twice daily, 12 hours apart, taken with food.
None Documented
None Documented
Terminal elimination half-life is approximately 41 hours, supporting once-daily dosing. Steady-state is reached within 8 days.
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Approximately 88% of the administered dose is eliminated via feces (with 85% as unchanged parent drug), and 8% via urine (with <5% as unchanged drug). Biliary excretion is the primary route for unchanged drug.
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor